PDF-PRE SET A RCH ITECTU RAL OWNERS MANU AL oug Fl eenor D esi gn or bet C any on Road Ar

T hese pr eset s ar e r ecor ded by capt ur ng t he o ut put of a 512 consol e Each pr eset can hen be a ssi gned a un que ade e f om 0 o 99 9 seco nds Pr eset s ar e r ecal ed b pr essi ng o ne o t he b ut ons ys te c b c te b y u in o o m s ta tio. mike.south@rch.org.au Hourly maintenance intravenous fluid requirements[Resuscitation bolus 10-20 ml/kg]Weight (kg) 243240444852607080 1. Check weight of patient2. Check maintenance fluids infusion r Recognition of danger signals. Distinguish self or damaged . self versus non-self. – fundamental to any immune system. PAMP or MAMP – pathogen/microbe-associated molecular pattern. DAMP – damage-associated molecular . 400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV. > . 18 years. Chronic HCV infection. Genotype . 2. Naïve . or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. > . 18 years. HCV infection. G. enotype 1 or 4. Failure to a prior therapy with . SOF ± RBV + (SMV or DCV or LDV) . with documented presence of . NS5A or NS3 RASs at failure . Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. W24. SOF/VEL. >. 18 years. Chronic HCV infection. Genotype 1 to 6. Naïve or treatment-experienced. No prior treatment with . NS5A or NS5B inhibitor. Child-Pugh B cirrhosis **. No . hepatocellular. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Nyt menighedsråd tiltræder. Februar 2013:. Nyt provstiudvalg er valgt. Maj 2013:. Provstiudvalget godkender financiering med byggestart januar 2014. Byggeudvalg udpeges:. Jesper Nørgaard. Hans Jørgen Sørensen. An overview). February, 2016. Agenda. RCH portal- Key Features. Introduction about the RCH portal. Login into the RCH application by Health Workers. Latest news and notification on the RCH program. Image Library. John J. . Sepkoski. Jr. (University of Chicago). Database of ~36,000 . genera (. Bull. . Amer. Pal. ., 363). Lists taxonomy and . stratigraphic. ranges. Marine animals only. Limitations:. Few soft-bodied animals.